Africa–Europe Research Partnership

WANECAM 3

Advancing next-generation antimalarial treatments

An Africa–Europe research partnership advancing next generation non-artemisinin antimalarial combinations towards a potential single dose cure for uncomplicated malaria.

Discover Our Work
Learn More

Africa–Europe Research Partnership

WANECAM 3

Advancing next-generation antimalarial treatments

An Africa–Europe research partnership advancing next generation non-artemisinin antimalarial combinations towards a potential single dose cure for uncomplicated malaria.

Discover Our Work
Learn More

Africa–Europe Research Partnership

WANECAM 3

Advancing next-generation antimalarial treatments

An Africa–Europe research partnership advancing next generation non-artemisinin antimalarial combinations towards a potential single dose cure for uncomplicated malaria.

Discover Our Work
Learn More

ABOUT WANECAM3

A Unified Network Against Malaria

WANECAM3 (West African Network for Clinical Trials of Antimalarial Drugs) 3rd version is an Africa–Europe research consortium dedicated to accelerating the development of next generation malaria treatments in response to the growing threat of antimalarial drug resistance.
Building on the experience and achievements of WANECAM1 and WANECAM2, WANECAM3 brings together African and European countries through research institutions, clinical trial sites, academic partners and product development partners.

Learn More

ABOUT WANECAM3

A Unified Network Against Malaria

WANECAM3 (West African Network for Clinical Trials of Antimalarial Drugs) 3rd version is an Africa–Europe research consortium dedicated to accelerating the development of next generation malaria treatments in response to the growing threat of antimalarial drug resistance.
Building on the experience and achievements of WANECAM1 and WANECAM2, WANECAM3 brings together African and European countries through research institutions, clinical trial sites, academic partners and product development partners.

Learn More

Global Health Burden

The Challenge

M
Malaria cases reported globally in 2023
~K
Deaths reported in 2023, primarily African children.
Threats
Partial artemisinin resistance & multi-day compliance failure
STRATEGIC MISSION

“To achieve a single dose cure for uncomplicated falciparum malaria.”

WANECAM3 aims to combine novel, potent, non-artemisinin antimalarial drugs to
ensure rapid parasite clearance, protect against reinfection, and build a high barrier to
drug resistance.

Strategic Goals

Objectives

01

Phase 2 & 3 Trial Data

Generate Phase 2 and 3 clinical trial data on novel non-artemisinin combinations.

02

Single-Dose Approval

Advance a promising single-dose combination through Phase 3 towards regulatory approval.

03

Resistance & Transmission

Assess transmission blocking activity and monitor antimalarial drug resistance.

STRATEGIC MISSION

Governance

WANECAM3 brings together 11 partner institutions from Africa and Europe under a coordinated governance structure designed to ensure effective project management, strong scientific leadership and high-quality implementation of the project’s clinical and research activities.

Operational Structure

Work Packages

WP1 ⚙️
Project Coordination & Admin

Overall management, financial governance and administrative oversight.

Lead: Amsterdam UMC
Explore WP1 →
WP2 🔬
Scientific Leadership

Strategic direction, clinical trial design and scientific protocol alignment.

Lead: USTTB
Explore WP2 →
WP3 🩺
Clinical Trials

Execution of multicenter clinical trials in pediatric and adult cohorts.

Lead: Novartis
Explore WP3 →
View all

Consortium Partners

Our Collaborators

Our Financial Partners

Global Health EDCTP3
Global Health EDCTP3
Novartis
MMV (Medicines for Malaria Venture)

Our Research Partners

Addis Ababa Univ
Amsterdam UMC
CERMEL
KEMRI | Wellcome
LSHTM
Makerere Univ
Univ of Tübingen
USTTB Bamako
PMRTC